Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas (original) (raw)

. 1996 Apr;148(4):1139–1152.

Abstract

Gliomas are malignant brain tumors, which, despite recent progress in surgical and radiological treatment, still have a poor prognosis. Since gliomas apparently resist immunological clearance mechanisms, we became interested in examining bow gliomas resist killing by the human complement system. The resistance of human cells to complement-mediated damage is, in large part, mediated by specific inhibitors of complement:membrane cofactor protein (CD46), decay-accelerating factor (CD55), and protectin (CD59). In the present study we examined the expression of complement regulators in 14 human glioma tumors and in 7 glioma cell lines (U251, U87, HS683, U373, U138, U118, and H2). Protectin was found to be strongly expressed by all glioma tumors and cell lines. Northern blotting analysis demonstrated the typical pattern of four to five protectin mRNAs in the glioma cells. Except for blood vessels, the expression of decay-accelerating factor was weak or absent in the tumors in situ, whereas in the cell lines its expression varied, ranging from negative to intermediate. Membrane cofactor protein was moderately expressed by all the cell lines but only weakly in the tumors. Cell-killing experiments demonstrated that the glioma cell lines were exceptionally resistant to C-mediated lysis. Five of the seven cell lines (U373, HS683, U118, U138, and H2) resisted complement lysis under conditions where most other cell lines were sensitive to killing. Neutralization experiments using specific monoclonal antibodies indicated that protectin was functionally the most important complement regulator in the glioma cells. The killing of the U87 and U251 cells could be significantly increased by a blocking anti-protectin monoclonal antibody, whereas for the other cell lines only moderate or no response was observed. The H2 cell line resisted killing by all antibodies and by complement. These results show that protectin is the most important complement regulator on human glioma cells. The exceptional complement resistance of some glioma cell lines suggests that they may utilize other, hitherto less well characterized, mechanisms to resist complement killing.

1139

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barba D., Saris S. C., Holder C., Rosenberg S. A., Oldfield E. H. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg. 1989 Feb;70(2):175–182. doi: 10.3171/jns.1989.70.2.0175. [DOI] [PubMed] [Google Scholar]
  2. Bjørge L., Vedeler C. A., Ulvestad E., Matre R. Expression and function of CD59 on colonic adenocarcinoma cells. Eur J Immunol. 1994 Jul;24(7):1597–1603. doi: 10.1002/eji.1830240722. [DOI] [PubMed] [Google Scholar]
  3. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  4. Danik M., Chabot J. G., Mercier C., Benabid A. L., Chauvin C., Quirion R., Suh M. Human gliomas and epileptic foci express high levels of a mRNA related to rat testicular sulfated glycoprotein 2, a purported marker of cell death. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8577–8581. doi: 10.1073/pnas.88.19.8577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Davies A., Simmons D. L., Hale G., Harrison R. A., Tighe H., Lachmann P. J., Waldmann H. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med. 1989 Sep 1;170(3):637–654. doi: 10.1084/jem.170.3.637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fearon D. T. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc Natl Acad Sci U S A. 1979 Nov;76(11):5867–5871. doi: 10.1073/pnas.76.11.5867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gasque P., Ischenko A., Legoedec J., Mauger C., Schouft M. T., Fontaine M. Expression of the complement classical pathway by human glioma in culture. A model for complement expression by nerve cells. J Biol Chem. 1993 Nov 25;268(33):25068–25074. [PubMed] [Google Scholar]
  8. Gasque P., Julen N., Ischenko A. M., Picot C., Mauger C., Chauzy C., Ripoche J., Fontaine M. Expression of complement components of the alternative pathway by glioma cell lines. J Immunol. 1992 Aug 15;149(4):1381–1387. [PubMed] [Google Scholar]
  9. Gordon D. L., Sadlon T., Hefford C., Adrian D. Expression of CD59, a regulator of the membrane attack complex of complement, on human astrocytes. Brain Res Mol Brain Res. 1993 Jun;18(4):335–338. doi: 10.1016/0169-328x(93)90098-a. [DOI] [PubMed] [Google Scholar]
  10. Hakulinen J., Meri S. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells. Lab Invest. 1994 Dec;71(6):820–827. [PubMed] [Google Scholar]
  11. Ingram M., Shelden C. H., Jacques S., Skillen R. G., Bradley W. G., Techy G. B., Freshwater D. B., Abts R. M., Rand R. W. Preliminary clinical trial of immunotherapy for malignant glioma. J Biol Response Mod. 1987 Oct;6(5):489–498. [PubMed] [Google Scholar]
  12. Jacobs S. K., Wilson D. J., Kornblith P. L., Grimm E. A. Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report. J Neurosurg. 1986 May;64(5):743–749. doi: 10.3171/jns.1986.64.5.0743. [DOI] [PubMed] [Google Scholar]
  13. Jenne D. E., Tschopp J. Clusterin: the intriguing guises of a widely expressed glycoprotein. Trends Biochem Sci. 1992 Apr;17(4):154–159. doi: 10.1016/0968-0004(92)90325-4. [DOI] [PubMed] [Google Scholar]
  14. Johnstone R. W., Loveland B. E., McKenzie I. F. Identification and quantification of complement regulator CD46 on normal human tissues. Immunology. 1993 Jul;79(3):341–347. [PMC free article] [PubMed] [Google Scholar]
  15. Jokiranta T. S., Meri S. Biotinylation of monoclonal antibodies prevents their ability to activate the classical pathway of complement. J Immunol. 1993 Aug 15;151(4):2124–2131. [PubMed] [Google Scholar]
  16. Junnikkala S., Hakulinen J., Meri S. Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of human melanoma cells. Eur J Immunol. 1994 Mar;24(3):611–615. doi: 10.1002/eji.1830240318. [DOI] [PubMed] [Google Scholar]
  17. Jäskeläinen J., Kalliomäki P., Paetau A., Timonen T. Effect of LAK cells against three-dimensional tumor tissue. In vitro study using multi-cellular human glioma spheroids as targets. J Immunol. 1989 Feb 1;142(3):1036–1045. [PubMed] [Google Scholar]
  18. Koretz K., Brüderlein S., Henne C., Möller P. Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium. Br J Cancer. 1993 Nov;68(5):926–931. doi: 10.1038/bjc.1993.456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Markwell M. A., Haas S. M., Tolbert N. E., Bieber L. L. Protein determination in membrane and lipoprotein samples: manual and automated procedures. Methods Enzymol. 1981;72:296–303. doi: 10.1016/s0076-6879(81)72018-4. [DOI] [PubMed] [Google Scholar]
  20. Merchant R. E., Merchant L. H., Cook S. H., McVicar D. W., Young H. F. Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor. Neurosurgery. 1988 Dec;23(6):725–732. doi: 10.1227/00006123-198812000-00007. [DOI] [PubMed] [Google Scholar]
  21. Meri S., Mattila P., Renkonen R. Regulation of CD59 expression on the human endothelial cell line EA.hy 926. Eur J Immunol. 1993 Oct;23(10):2511–2516. doi: 10.1002/eji.1830231020. [DOI] [PubMed] [Google Scholar]
  22. Meri S., Morgan B. P., Davies A., Daniels R. H., Olavesen M. G., Waldmann H., Lachmann P. J. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology. 1990 Sep;71(1):1–9. [PMC free article] [PubMed] [Google Scholar]
  23. Meri S., Waldmann H., Lachmann P. J. Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest. 1991 Nov;65(5):532–537. [PubMed] [Google Scholar]
  24. Morgan B. P. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem J. 1989 Nov 15;264(1):1–14. doi: 10.1042/bj2640001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Morgan B. P., Meri S. Membrane proteins that protect against complement lysis. Springer Semin Immunopathol. 1994;15(4):369–396. doi: 10.1007/BF01837366. [DOI] [PubMed] [Google Scholar]
  26. Nicholson-Weller A., Burge J., Fearon D. T., Weller P. F., Austen K. F. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol. 1982 Jul;129(1):184–189. [PubMed] [Google Scholar]
  27. Rollins S. A., Zhao J., Ninomiya H., Sims P. J. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. J Immunol. 1991 Apr 1;146(7):2345–2351. [PubMed] [Google Scholar]
  28. Seya T., Turner J. R., Atkinson J. P. Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b. J Exp Med. 1986 Apr 1;163(4):837–855. doi: 10.1084/jem.163.4.837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Shinoura N., Heffelfinger S. C., Miller M., Shamraj O. I., Miura N. H., Larson J. J., DeTribolet N., Warnick R. E., Tew J. J., Menon A. G. RNA expression of complement regulatory proteins in human brain tumors. Cancer Lett. 1994 Nov 11;86(2):143–149. doi: 10.1016/0304-3835(94)90072-8. [DOI] [PubMed] [Google Scholar]
  30. Vedeler C., Ulvestad E., Bjørge L., Conti G., Williams K., Mørk S., Matre R. The expression of CD59 in normal human nervous tissue. Immunology. 1994 Aug;82(4):542–547. [PMC free article] [PubMed] [Google Scholar]
  31. Yoshida S., Tanaka R., Takai N., Ono K. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors. Cancer Res. 1988 Sep 1;48(17):5011–5016. [PubMed] [Google Scholar]